ORIGINAL RESEARCH

p70 Ribosomal Protein S6 Kinase Is a Checkpoint of Human Hepatic Stellate Cell Activation and Liver Fibrosis in Mice

Florian P. Reiter,1,2,3 Liangtao Ye,1,3,4 Andrea Ofner,1,3 Tobias S. Schiergens,5,6 Andreas Ziesch,1,3 Lydia Brandl,7 Najib Ben Khaled,1,3 Simon Hohenester,1,3 Ralf Wimmer,1,3 Renate Artmann,1,3 Yulong He,4 Serene M. L. Lee,5,6 Doris Mayr,7 Changhua Zhang,4 Alexander L. Gerbes,1,3 Julia Mayerle,1,3 Gerald Denk,1,3,8,* and Enrico N. De Toni1,3,*

1Department of Medicine II, University Hospital, LMU Munich, Munich, Germany; 2Division of Hepatology, Department of Medicine II, University Hospital Würzburg, Würzburg, Germany; 3Liver Center, University Hospital, LMU Munich, Munich, Germany; 4Center for Digestive Diseases, The Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China; 5Department of General, Visceral and Transplantation Surgery, University Hospital, LMU Munich, Munich, Germany; 6Biobank of the Department of General, Visceral and Transplantation Surgery, University Hospital, LMU Munich, Munich, Germany; 7Institute of Pathology, LMU Munich, Munich, Germany; and 8Transplantation Center Munich, University Hospital, LMU Munich, Munich, Germany

SUMMARY

Targets and medical approaches to prevent progression of chronic liver disease to liver fibrosis or cirrhosis are urgently needed. We describe p70S6K being dysregulated in human liver fibrosis and define this protein as checkpoint of human hepatic stellate cell activation and liver fibrosis in vivo. Furthermore, we provide a clinical viable approach to inhibit this protein by the employment of CEP-1347.

BACKGROUND & AIMS: Progression of chronic liver disease (CLD) to liver cirrhosis and liver cancer is a major global cause of morbidity and mortality. Treatment options capable of inhibiting progression of liver fibrosis when etiological treatment of CLD is not available or fails have yet to be established. We investigated the role of serine/threonine kinase p70 ribosomal protein S6 kinase (p70S6K) as checkpoint of fibrogenesis in hepatic stellate cells (HSCs) and as target for the treatment of liver fibrosis.

APPROACH & RESULTS: Immunohistochemistry was used to assess p70S6K expression in liver resection specimen. Primary human or murine HSCs from wild-type or p70S6K<sup>−/−</sup> mice as well as LX-2 cells were used for in vitro experiments. Specific small interfering RNA or CEP-1347 were used to silence or inhibit p70S6K and assess its functional relevance in viability, contraction and migration assays, fluorescence-activated cell sorting, and Western blot. These results were validated in vivo by a chemical model of fibrogenesis using wild-type and p70S6K<sup>−/−</sup> mice. Expression of p70S6K was significantly increased in human cirrhotic vs noncirrhotic liver-tissue and progressively increased in vitro through activation of primary human HSCs. Conversely, p70S6K induced fibrogenic activation of HSCs in different models, including the small interfering RNA-based silencing of p70S6K in HSC lines, experiments with p70S6K<sup>−/−</sup> cells, and the pharmacological inhibition of p70S6K by CEP-1347. These findings were validated in vivo as p70S6K<sup>−/−</sup> mice developed significantly less fibrosis upon exposure to CCl<sub>4</sub>.
CONCLUSIONS: We establish p70S6K as a checkpoint of fibrogenesis in vitro and in vivo and CEP-1347 as potential treatment option that can safely be used for long-term treatment. (Cell Mol Gastroenterol Hepatol 2022;13:95–112; https://doi.org/10.1016/j.jcmgh.2021.09.001)

Keywords: Fibrosis; Cirrhosis; Chronic Liver Disease; Transforming Growth Factor-β; Platelet-Derived Growth Factor BB.

Chronic liver disease (CLD) with its associated mortality and morbidity represents a considerable and increasing global socioeconomic problem. Independently of its underlying etiology, CLD can cause liver fibrosis, eventually progressing to liver cirrhosis and its complications. Once liver cirrhosis becomes clinically apparent, 5-year mortality without liver transplantation amounts to 85% owing to the clinical complication such as variceal bleeding, ascites, kidney failure, and the occurrence of hepatocellular carcinoma, currently the most common cause of death in patients with liver cirrhosis and the fourth most common cause of tumor-related death worldwide.

Several advances have been made in the therapy of CLD, the latest and most remarkable perhaps being the development of direct-acting antiviral agents for the treatment of chronic hepatitis C. However, for other CLD, an effective medical treatment is still lacking, only partially effective, or effective only in a subgroup of patients.

Establishing a medical treatment capable of directly targeting fibrogenesis and delaying or abolishing the progression of fibrosis will be indispensable to reduce CLD-related morbidity and mortality until causal treatment options are established. The relevance of this issue is highlighted by the epidemiological trend of nonalcoholic steatohepatitis (NASH), a condition poorly responsive to treatment and due to become the leading cause of CLD and mortality globally. Unfortunately, several promising agents, such as situzumab or selonsertib, failed to meet their primary endpoint of inhibiting fibrosis in the treatment of CLD.

The lack of treatment options in liver fibrosis to complement existing etiological treatment therefore represents an unmet medical need for an ever-increasing number of patients worldwide.

On the mechanistic level, liver fibrosis is thought to be caused mainly by hepatic stellate cells (HSCs) that, upon activation, transdifferentiate into myofibroblasts, cause deposition of extracellular matrix, and induce portal hypertension by contractility.

Fibroblastic activation of HSCs can, in turn, be initiated at different sites, eg, the activation of transforming growth factor-β (TGF-β) or of platelet-derived growth factor BB (PDGF-BB), 2 molecules that trigger intracellular signaling converging to activate the PI3K-AKT-mTOR signaling. However, attempts at blocking these receptors or the PI3K-AKT-mTOR axis by currently available agents poses several safety issues concerning long-term tolerability of their antiproliferative and immunosuppressive effects.

To establish a potentially accessible molecular target for antifibrotic treatment, we chose to investigate the serine/threonine kinase p70 ribosomal protein S6 kinase (p70S6K), a molecule phosphorylated downstream of mTOR and possibly representing a distal effector of fibrogenesis, with the rationale that its pharmacological inhibition could be safer and more tolerable than that of its upstream targets. To this regard, we also assessed the potential use of CEP-1347 as p70S6K inhibitor, an agent for which extensive clinical research has proved to be safe and very well tolerated for long-term treatment in a previous clinical phase III trial for Parkinson’s disease.

Results

*Authors share co-senior authorship.

Abbreviations used in this paper: α-SMA, α-smooth muscle actin; CLD, chronic liver disease; GFAP, glial fibrillary acidic protein; HSC, hepatic stellate cell; pmHSC, murine hepatic stellate cell; NASH, nonalcoholic steatohepatitis; p70S6K, p70 ribosomal protein S6 kinase; PDGF, platelet-derived growth factor; pHSC, primary human hepatic stellate cell; siRNA, small interfering RNA; TGF-β, transforming growth factor-β; WST, water-soluble tetrazolium; Wt, wild-type.

© 2021 The Authors. Published by Elsevier Inc. on behalf of the AGA Institute. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Most current article

https://doi.org/10.1016/j.jcmgh.2021.09.001
human HSCs (phHSCs) on uncovered plastic dishes for 13 days to induce their spontaneous transdifferentiation to activated myofibroblasts. We observed that the expected increase of α-SMA, a hallmark of activation in these cells over 3 different time points (on days 2, 7, and 13 after isolation) was accompanied by an increased expression of p70S6K, as shown by Western blot (Figure 3). In summary, both the histological examination and the progressive increase of p70S6K during HSC activation support the hypothesis that this molecule plays a causal role in the process of fibrogenesis.

Silencing of p70S6K counteracts TGF-β–dependent activation of LX-2 cells and spontaneous activation of isolated primary cells

To assess whether the observed increase of p70S6K is an actual cause of fibrogenic HSC activation, p70S6K was silenced by small interfering RNA (siRNA) both in LX-2 cells and in isolated phHSCs. As shown in Figure 4A, silencing of p70S6K inhibited the activation of HSCs, as judged by the lack of α-SMA expression upon co-incubation with TGF-β in LX-2 cells. Similar results were obtained with phHSCs plated on uncovered plastic wells and harvested after undergoing incubation for 7 days with siRNA targeting p70S6K or control siRNA (Figure 4B).

To further validate this observation, we assessed the activation of primary murine HSCs (pmHSCs) isolated from p70S6K−/− mice or syngeneic age-matched wild-type (Wt) control mice. While assessing the phenotype of spontaneous ageing of Wt vs p70S6K−/− mice, we did not detect differences in body to liver or spleen weight, or in liver serum biochemistry between the 2 strains (Figure 5A and B). Also, there were no differences in liver histology and

Figure 1. (See previous page). p70S6K staining is higher in cirrhotic vs healthy livers. (A) Representative images showing immunohistochemical staining of α-SMA and p70S6K in cirrhotic and healthy livers (brown staining and arrows). α-SMA staining is observed along the fibrous septa; p70S6K-positive cells are visible as clusters along or within the septa. (B) Immunohistochemical staining of α-SMA and p70S6K was quantified automatically from whole slide scans from the respective tissues samples. The data express the area with positive staining as a percentage of the total area (n = 5; **P < .01; t test). (C, D) A costaining of Hoechst (blue), p70S6K (green), and α-SMA or GFAP (both red) was performed in mice treated with vehicle (nonfibrotic control) or CCl4. Control mice show a lower expression of p70S6K vs CCl4-treated animals. The images show an overlapping (yellow) staining pattern of p70S6K (green) and α-SMA or GFAP (red). Scale bars = 100 μm.

Figure 2. Costaining of p70S6K and markers of nonparenchymal liver cells was done. (A) Costaining of Hoechst (blue), p70S6K (green), and (A) F4/80 or (B) CK19 (red) was performed in mice treated with vehicle or CCl4 (scale bars = 100 μm). (C) Costaining of Hoechst (blue), p70S6K (green), and α-SMA (red) was performed in human liver samples from patients with liver cirrhosis. An overlapping expression of p70S6K (green) and α-SMA (red) can be observed in the septa (scale bars = 100 μm). (D) Nuclear staining of p70S6K in cirrhotic liver tissue (scale bar = 20 μm).
fibrosis markers as judged by Western blot or Sirius red staining (Figure 5C–E). However, when we examined the ex vivo activation of pmHSCs isolated from p70S6K−/− mice vs Wt mice, we observed a significantly lower increase of α-SMA expression in pmHSCs isolated from p70S6K−/− mice in comparison with Wt mice throughout a 13-day time period (Figure 4C). This suggests that p70S6K regulates HSC response to activation by external fibrogenetic stimuli. The findings on p70S6K activation in these 3 model systems pointed to a causal role of p70S6K in determining activation of HSC and α-SMA expression in both human and murine cells.

**p70S6K knockout confers protection from liver fibrosis in mice**

To validate these results, an in vivo model was employed, with the hypothesis that a lesser degree of fibrosis should be expected in p70S6K−/− mice upon exposure to chemically induced fibrogenetic stimuli. Male Wt and p70S6K−/− mice were thus challenged for 12 weeks with CCl4 (Figure 6A). In agreement with the in vitro experiments, we observed that p70S6Kwt mice exhibited a much higher extent of fibrosis vs their p70S6K−/− counterpart, as measured by Sirius red and α-SMA staining of liver sections from the respective strains (Figure 6B). This was accompanied by numerically lower (though not significant) serum bilirubin values and hepatic Acta2 and collagen 1α1 messenger RNA expression (Figure 7).

**The effects of p70S6K silencing can be reproduced by CEP-1347 in vitro**

In a next set of experiments, we aimed at assessing whether p70S6K can be inhibited pharmacologically. To this purpose, we used CEP-1347, a kinase inhibitor which we established as an effective inhibitor of p70S6K (Figure 8A–C). When LX-2 cells were incubated with TGF-β in the presence or absence of CEP-1347, the activation of this HSC cell line was almost completely inhibited. Specifically, CEP-1347 strongly inhibited the induction of α-SMA, PDGF receptor-β, and collagen 1α1 protein-expression (Figure 9A–E) as well as the migratory capacity and the contractility of HSCs (Figure 10A–D). The capability of CEP-1347 to inhibit p70S6K was demonstrated by a significantly diminished phosphorylation of p70S6K when cells were incubated with TGF-β in the presence of CEP-1347 (Figure 8A). Similar results were obtained when PDGF-BB (a well-established inducer of the PI3K-AKT-mTOR signaling in HSCs)22,23 was used to activate HSCs (Figure 8B and C). In comparison, CEP-1347 did not show

---

**Figure 3. Expression of p70S6K increases during the activation of phHSCs.** (A) phHSCs were seeded on uncovered plastic to cause their activation. A time-dependent, progressive activation of HSCs is evident with increasing green immunofluorescence of α-SMA, which was most prominent on day 13 after isolation. (B) Likewise, a progressive increase of both α-SMA and p70S6K could be seen by Western blot (left panel). Densitometry of protein-expression were quantitated from at least 4 samples and expressed as density units relative to the baseline (right panel; *P < .05; **P < .01; analysis of variance).
any relevant effect on other kinases known to affect fibrogeneration (Figure 8A).

Interestingly, CEP-1347 induced a significant G2 cell cycle arrest (Figure 11), an effect that might contribute to decreased fibrogenesis of HSCs. However, the possibility that this occurred solely as a consequence of a loss of cell viability caused by CEP-1347, rather than as a consequence of a direct antifibrotic effect of this drug, was excluded by viability assays, Hoechst staining and fluorescence-activated cell sorting analysis, which failed to show a relevant decrease in cell...
viability or apoptosis within the time frame in which antifibrotic effects were observed (Figures 11 and 12). These results were further validated in experiments with phHSCs, showing that CEP-1347 inhibits p70S6K along with collagen 1α1 expression (Figure 13A and B). These results show that CEP-1347 effectively inhibits p70S6K, hereby counteracting the profibrotic effects of HSC activation in different models.

Discussion

Progression of liver disease to fibrosis and cirrhosis as unmet medical challenge

Many advances have been made in the prevention and causal treatment of CLD, including the widespread use of anti-Hepatitis B virus vaccines and antiviral drugs, with the latest and most significant achievement being the
development of direct-acting antiviral agents for the treatment of chronic hepatitis C.\textsuperscript{24} For other CLDs, however, causal treatment is still lacking or poorly effective. Until individual curative etiological treatment options are established for all etiologies of CLD, the development of direct-acting agents capable of preventing progression of CLD to liver cirrhosis and its complications represents an important strategy to reduce CLD-related mortality. The importance of this approach is exemplified by NASH, a condition poorly responsive to treatment and due to become the leading cause of CLD globally.\textsuperscript{25,26} However, attempts at establishing clinically successful primary antifibrotic agents have so far failed.\textsuperscript{11–13} While setting out to investigate alternative molecular targets for antifibrotic treatment, we chose to focus on p70S6K, as this molecule is located downstream of the PI3K-AKT-mTOR signaling, where several pathways of fibrogenesis converge. We speculated that p70S6K might be a potential downstream effector of fibrogenesis. Thus, we expect that the effects of its pharmacological inhibition should be restricted to the prevention of collagen deposition, limiting the possible spectrum of adverse effects common to upstream regulators of this axis. Three topics describe the main findings of our article and their clinical significance.

**P70S6K is a central mediator of fibrogenesis downstream of PI3K-AKT-mTOR signaling**

Firstly, we provide novel mechanistic data on fibrogenesis by describing p70S6K as a distal effector of fibrosis downstream of mTOR activation by consistent results obtained in cell lines, isolated primary cells, human tissues, and p70S6K\textsuperscript{−/−} mice. The several-fold increase of p70S6K staining observed in cirrhotic human tissue suggested that p70S6K plays an important role in fibrogenesis, an indication supported by the fact that p70S6K also progressively increased during the process of activation of isolated phHSCs in vitro. The causal role of p70S6K in inducing liver fibrosis was confirmed by experiments showing that (1) silencing of p70S6K abolishes activation in human HSCs (Figure 4A and B); (2) p70S6K\textsuperscript{−/−} HSCs are protected from fibrogenic activation (Figure 4C); (3) the effects of p70S6K silencing could be reproduced by CEP-1347, a clinically viable drug that we established as an effective inhibitor of p70S6K (Figure 8A–C); and (4) when exposed to CCl\textsubscript{4}, p70S6K\textsuperscript{−/−} mice exhibited decreased liver fibrosis compared with Wt mice (Figure 6). These results are in line with the body of evidence that established the importance of the PI3K-AKT-mTOR axis in determining liver fibrosis and with 2 previous reports assessing the role of p70S6K in a rodent NASH model\textsuperscript{27} and in bile acid–induced activation of HSCs.\textsuperscript{28} We are aware of the limitation of our study that we cannot totally rule out that p70S6K expressed in other cell types (including F4/80 and CK19-positive cells) might also contribute to fibrogenesis.

Staining of p70S6K was not limited to HSCs. Future studies using cell-specific knockout models may shed more light in the role of p70S6K in hepatic fibrogenesis in specific cell compartments. Nevertheless, the current knowledge on the role of HSCs in fibrogenesis supports a likely function of p70S6K as a checkpoint of liver fibrogenesis by HSC activation.

![Figure 7. CCl\textsubscript{4} challenge in Wt vs p70S6K\textsuperscript{−/−} mice. (A) Male Wt and p70S6K\textsuperscript{−/−} mice were challenged with CCl\textsubscript{4} for 12 weeks. Body, liver, and spleen weight; bilirubin; and messenger RNA expression of Acta2 and Collagen 1α1 were assessed (n = 3 per group).](image-url)
Clinical implications

However, our results are not only relevant in terms of the definition of the mechanistic role of p70S6K within the pathways regulating fibrogenesis; our finding defining CEP-1347 as an effective inhibitor of this molecule has important potential clinical implications. Owing to the role of PI3K-AKT-mTOR signaling in the regulation of immune response and cell proliferation, several inhibitors of PI3K (comprising copanlisib, duvelisib, or idelalisib) and mTOR (sirolimus, everolimus) have been approved as anticancer or immunosuppressive agents. However, the use of these substances to prevent the progression of liver fibrosis does not seem to be feasible in the setting of long-term treatment required to treat CLD, owing to potential adverse events anticipated by the well-known antiproliferative or immunosuppressive effects of these agents.

Figure 8. CEP-1347 does not inhibit phosphorylation of JNK, ERK1, ERK2, or SMAD2 but reduces phosphorylation of p70S6K in human HSCs (LX-2). Human LX-2 cells were stimulated with (A) TGF-β or (B, C) PDGF-BB and co-stimulated with 1000 nM CEP-1347 (CEP) for (A) 24 hours or (B, C) 1 hour. (A) Densitometry data of phosphorylated protein expression levels were normalized to that of unphosphorylated proteins. The results are illustrated as representative blots (at least 6 per group; *P < .05; **P < .01; analysis of variance). (B) Phosphorylation of p70S6K (pp70S6K) was assessed by immunomicroscopy (green) and compared with unphosphorylated p70S6K. (C) Protein expression of pp70S6K was quantified by densitometry. Densitometric values of p70S6K were normalized to unphosphorylated p70S6K (n = 13; * P < .05; analysis of variance).

Targeting p70S6K would restrict the blockage of PI3K-AKT-mTOR axis to its effect on liver fibrosis without interfering with the actions of the upstream members of this signaling pathway, hereby representing a potentially safer and more tolerable therapeutic strategy. However, to our knowledge, no clinically viable p70S6K inhibitor had been previously described.

Clinical use of CEP-1347

Here, we suggest for the first time the kinase inhibitor CEP-1347 as an effective inhibitor of p70S6K. CEP-1347 was developed to treat Parkinson’s disease and has proved to be safe, well tolerated, and devoid of long-term unwanted effects in a large cohort of patients (cumulatively, 1467 patient-years). The extensive clinical data...
already available and the excellent safety profile of CEP-1347 fulfils a stringent prerequisite for its clinical assessment as a therapeutic agent for CLD and liver fibrosis, alone or in combination with established causal treatment of CLDs.

Conclusion

In summary, we describe p70S6K as a checkpoint of fibrogenesis and as an actionable target for CEP-1347, a clinically viable and available compound that can safely be administered for long-term treatment. Further studies
should be conducted to investigate p70S6K as a therapeutic target to treat CLD.

**Materials And Methods**

**Cell lines**

LX-2 cells were purchased from Merck Millipore (Darmstadt, Germany). Their authenticity was assessed by the Leibniz-Institut (DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH), and confirmed based on DNA-fingerprinting.

**Human samples**

The use of all human material presented in this article was approved by the ethics committee of the Faculty of Medicine of the University of Munich (Project ID: 17-619). The material was provided by the Biobank under the administration of the Human Tissue and Cell Research Foundation at the Hospital of the University of Munich. The framework of the Human Tissue and Cell Research Foundation ([http://www.htcr.org](http://www.htcr.org)) includes written informed consent from all donors, and had been previously approved by the ethics committee of our institution (approval Nr. 025-12) as well as by the Bavarian State Medical Association (approval Nr. 11142). The biobank and the cell isolation core facility of the department of surgery have implemented total quality management and are certified to ISO 9001:2008. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution’s human research committee.

**Cell culture**

Cells were kept in Iscove Basal Medium (Merck Millipore; phHSCs) or in Dulbecco’s modified Eagle medium (Sigma-Aldrich, Darmstadt, Germany; pmHSCs and LX-2 cells) containing 2% (LX-2) or 10% (phHSCs and pmHSCs) fetal bovine serum (Merck Millipore) and antibiotics (Sigma-Aldrich). All cells were cultivated in a humidified atmosphere with 5% CO₂ and 21% O₂ at 37°C. LX-2 cells were stimulated with 10 ng/mL TGF-β (PeproTech, Hamburg, Denmark).
Germany) or 30 ng/mL PDGF-BB (Biomol, Hamburg, Germany) and co-incubated with 1000 nM CEP-1347 (Tocris, Bristol, United Kingdom) for 1 hour, 24 hours, or 48 hours, where indicated. pHSCs and pmHSCs were cultured on uncovered plastic dishes for up to 13 days to induce a spontaneous activation. For these long-term experiments, culture media in pHSCs were replaced with fresh media and CEP-1347 3 times a week.

Isolation of pHSCs
A liver cell suspension was prepared using a 2-step collagenase perfusion technique with modifications as described previously. In brief, hepatocytes were removed by multiple cycles of low-speed centrifugation, which resulted in a supernatant that contained the non-parenchymal cells. pHSCs were subsequently purified from the nonparenchymal cell fraction by discontinuous density centrifugation using Percoll. Quality of isolation was checked using immunocytomicroscopy against α-SMA (Sigma-Aldrich), Desmin (Sigma-Aldrich), GFAP (Sigma-Aldrich), and CK-19 (Merck Millipore) (Figure 14).

Isolation of pmHSCs
Isolation of pmHSCs was performed by pronase-collagenase perfusion followed by density gradient centrifugation in 13.2% Nycodenz (Axis-Shield PoC, Oslo, Norway) as described previously.

Viability assays
The effect of CEP-1347 on cell viability was assessed by 2 kinds of viability assays—PicoGreen (Invitrogen, Waltham, MA) and by water-soluble tetrazolium assay (Promega, Walldorf, Germany)—according to the instructions provided by the manufacturers.

Western blot
Proteins were loaded in equal amounts and separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membranes (Merck Millipore). Membranes were incubated with the primary antibodies directed against the following molecules: α-SMA (Sigma-Aldrich) PDGF receptor-β (Cell Signaling Technology, Danvers, MA), collagen 1α1 (R&D Systems, Minneapolis, MN), JNK, phospho-JNK (pJNK), ERK1/2, phospho-ERK1/2 (pERK), SMAD2, phospho-SMAD2 (pSMAD2), AKT, phospho-AKT (pAKT), p70S6K, phospho-p70S6K (pp70S6K) (all from Cell Signaling Technology), GAPDH (Abcam, Cambridge, United Kingdom) and β-actin (Sigma-Aldrich). The following secondary antibodies were used as needed: a goat-anti-mouse-IgG-HRP antibody (Bio-Rad, Feldkirchen, Germany), a goat-anti-rabbit-IgG-HRP antibody (Bio-Rad), or a goat-anti-sheep-IgG-HRP antibody (R&D Systems). Visualization was performed using the ChemiDoc INTAS, Homburg, Germany) after incubation with Clarity Western ECL Substrate (Bio-Rad).

Real-time polymerase chain reaction
Real-time polymerase chain reaction was performed in a SYBR Green system (Quantitect SYBR Green PCR Kit; Qiagen, Venlo, the Netherlands) using a LightCycler 96 (Roche, Penzberg, Germany). Expression was calculated according to the ΔΔCt method with Gapdh and 36b4 as the housekeeping genes and normalized to the means of the controls. The following primer sequences were used:

Gapdh: Fwd.: AGTATGACTCCA CACTCACGCC Rev.: ATGTTAGGGGTCTCGCTC
36b4: Fwd.: TCTAGGACCCGAGAGACCT Rev.: CCCACCTTGTCTCCAGTCTT
Acta2: Fwd.: GAGACTCTCTTCCAGCCATCTT Rev.: CCCCTGACAGCGTGTGTACG
Collagen 1α1: Fwd.: CCTGGCAAACAAGGTCCTTC Rev.: CCCGTACAGCGTGGTACG

Hoechst staining and immunocytomicroscopy
Cells were stimulated for 24 hours with 1000 nM CEP-1347 before undergoing incubation with Hoechst 33342 (Fluka, Buchs, Switzerland). For immunocytomicroscopy studies, human or murine liver tissues were used for p70S6K or α-SMA immunohistochemical staining. p70S6K monoclonal rabbit antibody (Cell Signaling Technology) and phospho-p70S6K (Cell Signaling Technology) were used as secondary antibodies, an Alexa-Fluor 488 goat anti-mouse IgG or goat anti-rabbit IgG was used. Hoechst or phalloidin (Invitrogen) were used as counterstains. Microscopy was performed using a Zeiss Axiovert TV 135 (Zeiss, Oberkochen, Germany).

Immunohistochemistry and immunofluorescence
Paraffin-embedded sections (3 μm) of primary human or primary murine liver tissues were used for p70S6K or α-SMA immunohistochemical staining, p70S6K monoclonal rabbit antibody (Cell Signaling Technology) or α-SMA polyclonal rabbit antibody (Abcam) were applied as primary antibodies and detected by EnVision+ System-HRP–labeled polymer anti-rabbit (Dako, Santa Clara, CA). For immunofluorescence studies, human or murine liver tissues were...
co-incubated with p70S6K monoclonal rabbit antibody (Cell Signaling Technology) and anti-α-SMA monoclonal mouse antibody (Sigma-Aldrich), GFAP mouse antibody (Sigma-Aldrich), F4/80 monoclonal mouse antibody (Santa Cruz Biotechnology, Dallas, TX), CK19 monoclonal mouse antibody (Proteintech, Rosemont, IL), or monoclonal mouse antibody in 5% bovine serum albumin (Merck Millipore), and detected with Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen, Darmstadt, Germany) and Alexa Fluor 594 goat anti-mouse IgG (Invitrogen). Nuclei were counterstained with Vectashield (Vector Laboratories, Burlingame, CA) containing Hoechst 33342 (Sigma-Aldrich). Pictures were taken using the Leica fluorescence microscope (Leica Microsystems, Wetzlar, Germany).

Figure 12. Effect of CEP-1347 on apoptosis and cell viability in LX-2 cells. (A) The effect of CEP-1347 (CEP) on apoptosis was assessed in LX-2 cells by Hoechst 33342 staining, which failed to show alteration of nuclear chromatin staining upon incubation with CEP-1347 at the concentration of 1000 nM vs control cells. (B, C) No decrease of cell viability was detected by using water-soluble tetrazolium assays and Pico-Green 24 and 48 hours after stimulation with the indicated concentrations of CEP-1347 (data are representative of measurement from at least 4 different experiments).
Si-RNA silencing

p70S6K siRNA was purchased from Qiagen; β-galactosidase siRNA, which was used as a control, was purchased from Dharmacon (Lafayette, CO). Lipofectamin 2000 (Invitrogen) was used as transfectant for siRNA experiments.

Quantification of positive stained area

Slides from human or murine liver tissue were scanned as indicated after Sirius red or after immunohistochemical staining of p70S6K, α-SMA, and collagen 1α1 using a Panoramic MIDI II digital slide scanner from 3D-Histech (Sysmex, Norderstedt, Germany). The stained fibrotic area was quantified via QuPath software (https://qupath.github.io/) and ImageJ2 software (National Institutes of Health, Bethesda, MD) as described previously.35
LX-2 cells were treated 48 hours after transfection with 10 ng/mL TGF-β for 24 hours. For siRNA transfection in pHSCs, cells were cultured on uncovered plastic for 7 days. Transfection with the respective p70S6K and control siRNA was performed on day 2 and day 5.

**Fluorescence-activated cell sorting**

For analysis of cell cycle, cells were stimulated with PDGF-BB, CEP-1347 or their combination for 24 hours before being harvested and undergoing propidium iodide staining (Sigma, Germany) as described previously. Fluorescence-activated cell sorting analysis was performed by using the Accuri C6 flow cytometer (BD Biosciences, Franklin Lakes, NJ) and its built-in software.

**Gel-contraction assay**

The gel-contraction assay was performed according to the method described by Ikenaga et al. After polymerization of the collagen, the gel was mobilized from the surface using a pipette tip. Medium containing stimulating agents was added to the gels. After 24 hours of incubation, the gel area was measured using ImageJ software. The ratio of the well area to the gel area was calculated.

**Migration assay**

LX-2 cells were seeded in 6-well plates. When cells reached confluence, a horizontal scratch was made with the tip of a 100-μL pipette. Afterward, the wells were washed once with cell culture medium and stimulated with the different agents for 24 hours. Images were acquired before and after incubation with these agents to determine (ImageJ software) the reduction of the initial cell-free area as marker of cell migration activity.

**Animal experiments**

Liver fibrosis was induced using CCl₄ (Sigma-Aldrich) dissolved in corn oil (Sigma-Aldrich) as described previously. Male C57BL/6 p70S6K⁺/⁻ (Wt) vs p70S6K⁻/⁻ mice were bred from p70S6K⁺/⁻ mice (purchased from RIKEN (Tokyo, Japan)) and challenged 3 times weekly with intraperitoneal injections of CCl₄. A first dose of 0.25-mL CCl₄ per kg body weight was administered when animals reached the eighth week of age and was followed by injections of 0.5-mL CCl₄ per kg body weight for altogether 3 months. Animals were kept on a 12-hour light/dark cycle, fed ad libitum, and received human care in compliance to the standard local and international regulations outlined in the Guide for the Care and Use of Laboratory Animals. All experiments were approved by the local authorities (Regierung von Oberbayern). All experiments conforms to the ARRIVE guidelines.

**Figures**

Figures were created using GraphPad Prism 7 (GraphPad Software, San Diego, CA) or Adobe Illustrator CC 2019 (Adobe, San Jose, California).

**Statistical analysis**

Statistical calculations were performed by using SPSS 25 (IBM, Armonk, NY) or GraphPad Prism 7 using analysis of variance, t test, Mann-Whitney U test, or Wilcoxon or Kruskal-Wallis test as indicated in the presentation of the specific experiments. When a relevant influence of an experiment was observed, univariate analysis of variance was performed and degrees of freedom, means of squares, and F values were calculated. P values lower than .05 were referred to as statistically significant. All data are presented as mean ± SEM.

**References**

1. GBD 2017 Cirrhosis Collaborators. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020;5:245–266.
2. Mezzano G, Juanola A, Cardenas A, Mezey E, Hamilton JP, Pose E, Graupera I, Gines P, Sola E, Hernaez R. Global burden of disease: acute-on-chronic liver failure, a systematic review and meta-analysis. Gastroenterology 2020;162:929–937.
3. Williams R. Global challenges in liver disease. Hepatology 2006;44:515–521.
4. De Toni EN, Schlesinger-Raab A, Fuchs M, Schepp W, Nyberg M, Geisler F, Ricke J, Paprottka P, Friess H, Werner J, Gerbes AL, Mayerle J, Engel J. Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study. Gut 2020;69:168–176.
5. Gerbes A, Zoulim F, Tilg H, Dufour JF, Bruix J, Paradis V, Salem R, Peck-Radosavljevic M, Galle PR, Greten TF, Nault JC, Avila MA. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma. Gut 2018;67:380–388.
6. Carrat F, Fontaine H, Dorival C, Simony M, Diao A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronnowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouilleres O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Abergel A, Cales P, Ganne N, Loustaud-Ratti V, D’Alteroche L, Caussé X, Geist C, Minello A, Rosa I, Gelu-Simeon M, Portal I, Raffi F, Bourliere M, Pol S, French. ANRS CO22 HepAther cohort. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019;393:1453–1464.
7. Younossi ZM, Golab P, de Avila L, Paik JM, Shrishord M, Fukui N, Qiu Y, Burns L, Afendy A, Nader F. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol 2019;71:793–801.
8. Simon TG, Roelstraete B, Khalili H, Hagstrom H, Ludvigsson JF. Mortality in biopsy-confirmed...
nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 2021;70:1375–1382.

11. Muir AJ, Levy C, Janssen HLA, Montano-Loza AJ, Shiffman ML, Caldwell S, Luketic V, Ding D, Jia C, McColgan BJ, McHutchinson JG, Mani Subramanian G, Myers RP, Manns M, Chapman R, Afshar NH, Goodman Z, Eksteen B, Bowlus CL. GS-US-321-0102 Investigators. Simituzumab for primary sclerosing cholangitis: phase 2 study results with insights on the natural history of the disease. Hepatology 2019;69:684–698.

12. Harrison SA, Abdelmalek MF, Caldwell S, Shiffman ML, Diehl AM, Ghalib R, Lawitz EJ, Rockey DC, Schall RA, Jia C, McColgan BJ, McHutchinson JG, Subramanian GM, Myers RP, Younossi Z, Ratziu V, Muir AJ, Afshar NH, Goodman Z, Bosch J, Sanyal AJ. GS-US-321-0105 and GS-US-321-0106 Investigators. Simituzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis. Gastroenterology 2018;155:1140–1153.

13. Harrison SA, Wai-Sun Wong V, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, Kohli A, Sarin S, Caldwell SH, Alkhouri N, Shiffman ML, Camargo M, Li G, Kersey K, Jia C, Zhu Y, Dijedjos CS, Subramanian GM, Myers RP, Gunn N, Sheikh A, Anstee QM, Romero-Gomez M, Trauner M, Goodman Z, Lawitz EJ, Younossi Z. STELLAR-3 and STELLAR-4 Investigators. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized phase III STELLAR trials. J Hepatol 2020;73:26–39.

14. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000;275:2247–2250.

15. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209–218.

16. Reynaert H, Thompson MG, Thomas T, Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002;50:571–581.

17. Pinzani M, Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001;21:397–416.

18. Reeves HL, Friedman SL. Activation of hepatic stellate cells—a key issue in liver fibrosis. Front Biosci 2002;7:d808–d826.

19. Zhang YE. Non-Smad signaling pathways of the TGF-β family. Cold Spring Harb Perspect Biol 2017;9:a022129.

20. Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007;69:1480–1490.

21. Reiter FP, Hohenester S, Nagel JM, Wimmer R, Artmann R, Wottke L, Makenchis MC, Mayr D, Rust C, Trauner M, Denk GU. 1,25-(OH)(2)-vitamin D(3) prevents activation of hepatic stellate cells in vitro and ameliorates inflammatory liver damage but not fibrosis in the Aβbb4(−/−) model. Biochem Biophys Res Commun 2015;459:227–233.

22. Marra F, Pinzani M, DeFranco R, Laffi G, Gentilini P. Involvement of phosphatidylinositol 3-kinase in the activation of extracellular signal-regulated kinase by PDGF in hepatic stellate cells. FEBS Lett 1995;376:141–145.

23. Marra F, Gentilini A, Pinzani M, Choudhury GG, Parola M, Herbst H, Dianzani MU, Laffi G, Abбудou HE, Gentilini P. Phosphatidylinositol 3-kinase is required for platelet-derived growth factor’s actions on hepatic stellate cells. Gastroenterology 1997;112:1297–1306.

24. Lee YA, Friedman SL. Reversal, maintenance or progression: what happens to the liver after a virologic cure of hepatitis C? Antiviral Res 2014;107:23–30.

25. Williams CD, Stengel J, Aiske MI, Torres DM, Shaw J, Contreras M, Landt CL, Harrison SA. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124–131.

26. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62:S47–S64.

27. Cai CX, Buddha H, Castelino-Prabhu S, Zhang Z, Britton RS, Bacon BR, Neuschwander-Tetri BA. Activation of insulin-Pi3K/Akt-p70S6K pathway in hepatic stellate cells contributes to fibrosis in nonalcoholic steatohepatitis. Dig Dis Sci 2017;62:968–978.

28. Svegliati-Baroni G, Ridolfi F, Hannivoort R, Saccomanno S, Homan M, De Minicis S, Jansen PL, Candelaresi C, Benedetti A, Moshegh H. Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor. Gastroenterology 2005;128:1042–1055.

29. Sadeghi N, Gerber DE. Targeting the PI3K pathway for cancer therapy. Future Med Chem 2012;4:1153–1169.

30. Yang J, Nie J, Ma X, Wei Y, Peng Y, Wei X. Targeting PI3K in cancer: mechanisms and advances in clinical trials. Mol Cancer 2019;18:26.

31. Schiwid SR, Bausch J, Oakes D, Schuchter L, Tanner C, Forrest M, Lang AE, Shoulson I, Shoulson I, Hyson C, Forre M, Lang AE, Shoulson I, Hyson C, Oakes D, Flagg E, Rudolph A, Kieburtz K, Lang A, Fahn S, Gauger L, Goetz C. Cancer incidence in a trial of an antiapoptotic agent for Parkinson’s disease. Mov Disord 2010;25:1801–1808.

32. Thasler WE, Weiss TS, Schillhorn K, Stoll PT, Irgang B, Jauch KW. Charitable state-controlled foundation human tissue and cell research: ethic and legal aspects in the supply of surgically removed human tissue for research in the academic and commercial sector in Germany. Cell Tissue Bank 2003;4:49–56.

33. Lee SM, Schiergns TS, Demmel M, Thasler RM, Thasler WE. Isolation of hepatocytes and stellate cells from a single piece of human liver. Methods Mol Biol 2017;1506:247–258.

34. Lee SM, Schelcher C, Demmel M, Hauner M, Thasler WE. Isolation of human hepatocytes by a two-step collagenase perfusion procedure. J Vis Exp 2013;79:56.
Popov YV. Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut 2017;66:1697–1708.

Received March 15, 2021. Accepted September 8, 2021.

Correspondence
Address correspondence to: Florian P. Reiter, MD, Department of Medicine II, Liver Center Munich, University of Munich, Marchioninistraße 15, D-81377 Munich, Germany. e-mail: reiter_f@ukw.de; fax: +49-931-201-640023.

Acknowledgments
The authors thank Sebastian Reiter for his support with the illustration of the graphical abstract.

CRediT Authorship Contributions
Florian Paul Reiter, MD (Conceptualization: Lead; Data curation: Equal; Formal analysis: Lead; Funding acquisition: Lead; Investigation: Equal; Methodology: Equal; Project administration: Lead; Resources: Equal; Software: Equal; Supervision: Lead; Validation: Equal; Visualization: Equal; Writing – original draft: Lead; Writing – review & editing: Lead).

Najib Ben Khaled, MD (Conceptualization: Supporting; Data curation: Support; Formal analysis: Supporting; Investigation: Supporting; Methodology: Supporting; Software: Supporting).

Alexander Gerbes, MD (Supervision: Supporting; Writing – original draft: Supporting; Writing – review & editing: Supporting).

Florian Reiter, MD (Supervision: Lead; Validation: Lead; Resources: Equal; Project administration: Equal; Funding acquisition: Equal; Investigation: Lead; Project administration: Equal; Resources: Lead; Supervision: Lead; Validation: Lead; Writing – original draft: Lead; Writing – review & editing: Lead).

Lydia Brandl, MD (Data curation: Supporting; Formal analysis: Supporting; Investigation: Supporting; Methodology: Supporting; Software: Supporting).

Enrico De Toni, MD (Conceptualization: Equal; Data curation: Equal; Formal analysis: Equal; Funding acquisition: Equal; Investigation: Equal; Project administration: Equal; Resources: Lead; Supervision: Lead; Validation: Lead; Writing –original draft: Lead; Writing – review & editing: Lead).

Tobias Schiergens, MD (Project administration: Equal; Resources: Equal; Formal analysis: Supporting; Investigation: Supporting; Methodology: Supporting).

Andreas Ziesch (Formal analysis: Supporting; Investigation: Supporting; Methodology: Supporting).

Lydia Brandl, MD (Data curation: Supporting; Formal analysis: Supporting; Methodology: Supporting; Visualization: Supporting).

Najib Ben Khaled, MD (Formal analysis: Supporting; Project administration: Supporting; Validation: Supporting; Writing – review & editing: Supporting).

Simon Hohenester, MD (Formal analysis: Supporting; Methodology: Supporting; Writing – review & editing: Supporting).

Ralf Wimmer (Data curation: Supporting; Formal analysis: Equal; Investigation: Supporting; Project administration: Supporting; Software: Supporting; Visualization: Supporting).

Renate Artmann (Data curation: Supporting; Formal analysis: Supporting).

Yulong He, MD (Writing – review & editing: Supporting).

Serene Lee, Dr. (Formal analysis: Supporting; Methodology: Supporting; Resources: Supporting; Visualization: Supporting).

Doris Mayr, MD (Formal analysis: Supporting; Methodology: Supporting; Supervision: Supporting; Writing – review & editing: Supporting).

Changhua Zhang, MD (Project administration: Supporting; Supervision: Supporting; Writing – review & editing: Supporting).

Julia Mayerle, MD (Validation: Supporting; Writing – original draft: Supporting; Writing – review & editing: Supporting).

Gerald Denk, MD (Project administration: Equal; Supervision: Equal; Writing – original draft: Equal; Writing – review & editing: Equal).

Enrico De Toni, MD (Conceptualization: Equal; Data curation: Equal; Formal analysis: Equal; Funding acquisition: Equal; Investigation: Equal; Project administration: Equal; Resources: Lead; Supervision: Lead; Validation: Lead; Writing –original draft: Lead; Writing – review & editing: Lead).

Conflicts of interest
These authors disclose the following: Florian P. Reiter has received honoraria for lectures and travel support from Falk Foundation and Gilead. Najib Ben Khaled has received reimbursement of meeting attendance fees and travel expenses from EISAI and lecture honoraria from Falk. Gerald Denk has received honoraria for lectures, teaching, advisory activities, and travel support from AbbVie, Alexion, Falk Foundation, Gilead, GMP Orphan, Intercept, and Novartis. Enrico De Toni has served as a paid consultant for AstraZeneca, Bayer, BMS, EISAI, Eli Lilly & Co, Pfizer, Ipsen, and Roche; received reimbursement of meeting attendance fees and travel expenses from Arqule, AstraZeneca, BMS, Bayer, Celion, and Roche; received lecture honoraria from BMS and Falk; and received third-party funding for scientific research from Arqule, AstraZeneca, BMS, Bayer, Eli Lilly, and Roche. The remaining authors disclose no conflicts.

Parts of this work were presented at the annual meeting of the German Society for Digestive and Metabolic Diseases 2020, and the work was selected as a BEST of DGVS Abstract (Z Gastroenterol 2020;58:e135). Furthermore, parts were presented at the latest Liver Meeting of the American Association for the Study of Liver Diseases (Hepatology 2020;72[S1]) and at the annual meeting of the Bavarian Society for Gastroenterology 2018 (Z Gastroenterol 2018;56:e22).

Funding
This work was supported by grants from the LMUexcellent investment fund of the Ludwig Maximilian University Munich, the National Natural Science Foundation of China (Grant Nos. 8200577 and 82073148), and the China Postdoctoral Science Foundation (Grant No. 2020M680135). The funding agencies were not involved in the study design and the data collection, analysis, and their interpretation.